Noémie Boillat-Blanco1, Kaushik L Ramaiya2, Maliwasa Mganga3, Lilian T Minja4, Pascal Bovet5, Christian Schindler6, Arnold Von Eckardstein7, Sebastien Gagneux6, Claudia Daubenberger6, Klaus Reither8, Nicole Probst-Hensch6. 1. Ifakara Health Institute Swiss Tropical and Public Health Institute Department of Sciences, University of Basel Infectious Diseases Service. 2. Shree Hindu Mandal Hospital Muhimbili University of Health Sciences. 3. Kinondoni Municipal Council, National Tuberculosis Program, Dar es Salaam, United Republic of Tanzania. 4. Ifakara Health Institute. 5. Institute of Social and Preventive Medicine, Lausanne University Hospital. 6. Swiss Tropical and Public Health Institute Department of Sciences, University of Basel. 7. Institute of Clinical Chemistry, University of Zurich, University Hospital of Zurich, Switzerland. 8. Ifakara Health Institute Swiss Tropical and Public Health Institute Department of Sciences, University of Basel.
Abstract
BACKGROUND: Diabetes mellitus (DM) increases tuberculosis risk while tuberculosis, as an infectious disease, leads to hyperglycemia. We compared hyperglycemia screening strategies in controls and patients with tuberculosis in Dar es Salaam, Tanzania. METHODS: Consecutive adults with tuberculosis and sex- and age-matched volunteers were included in a case-control study between July 2012 and June 2014. All underwent DM screening tests (fasting capillary glucose [FCG] level, 2-hour CG [2-hCG] level, and glycated hemoglobin A1c [HbA1c] level) at enrollment, and cases were tested again after receipt of tuberculosis treatment. Association of tuberculosis and its outcome with hyperglycemia was assessed using logistic regression analysis adjusted for sex, age, body mass index, human immunodeficiency virus infection status, and socioeconomic status. Patients with tuberculosis and newly diagnosed DM were not treated for hyperglycemia. RESULTS: At enrollment, DM prevalence was significantly higher among patients with tuberculosis (n = 539; FCG level > 7 mmol/L, 4.5% of patients, 2-hCG level > 11 mmol/L, 6.8%; and HbA1c level > 6.5%, 9.3%), compared with controls (n = 496; 1.2%, 3.1%, and 2.2%, respectively). The association between hyperglycemia and tuberculosis disappeared after tuberculosis treatment (adjusted odds ratio [aOR] for the FCG level: 9.6 [95% confidence interval {CI}, 3.7-24.7] at enrollment vs 2.4 [95% CI, .7-8.7] at follow-up; aOR for the 2-hCG level: 6.6 [95% CI, 4.0-11.1] vs 1.6 [95% CI, .8-2.9]; and aOR for the HbA1c level, 4.2 [95% CI, 2.9-6.0] vs 1.4 [95% CI, .9-2.0]). Hyperglycemia, based on the FCG level, at enrollment was associated with tuberculosis treatment failure or death (aOR, 3.3; 95% CI, 1.2-9.3). CONCLUSIONS: Transient hyperglycemia is frequent during tuberculosis, and DM needs confirmation after tuberculosis treatment. Performance of DM screening at tuberculosis diagnosis gives the opportunity to detect patients at risk of adverse outcome.
BACKGROUND:Diabetes mellitus (DM) increases tuberculosis risk while tuberculosis, as an infectious disease, leads to hyperglycemia. We compared hyperglycemia screening strategies in controls and patients with tuberculosis in Dar es Salaam, Tanzania. METHODS: Consecutive adults with tuberculosis and sex- and age-matched volunteers were included in a case-control study between July 2012 and June 2014. All underwent DM screening tests (fasting capillary glucose [FCG] level, 2-hour CG [2-hCG] level, and glycated hemoglobin A1c [HbA1c] level) at enrollment, and cases were tested again after receipt of tuberculosis treatment. Association of tuberculosis and its outcome with hyperglycemia was assessed using logistic regression analysis adjusted for sex, age, body mass index, human immunodeficiency virus infection status, and socioeconomic status. Patients with tuberculosis and newly diagnosed DM were not treated for hyperglycemia. RESULTS: At enrollment, DM prevalence was significantly higher among patients with tuberculosis (n = 539; FCG level > 7 mmol/L, 4.5% of patients, 2-hCG level > 11 mmol/L, 6.8%; and HbA1c level > 6.5%, 9.3%), compared with controls (n = 496; 1.2%, 3.1%, and 2.2%, respectively). The association between hyperglycemia and tuberculosis disappeared after tuberculosis treatment (adjusted odds ratio [aOR] for the FCG level: 9.6 [95% confidence interval {CI}, 3.7-24.7] at enrollment vs 2.4 [95% CI, .7-8.7] at follow-up; aOR for the 2-hCG level: 6.6 [95% CI, 4.0-11.1] vs 1.6 [95% CI, .8-2.9]; and aOR for the HbA1c level, 4.2 [95% CI, 2.9-6.0] vs 1.4 [95% CI, .9-2.0]). Hyperglycemia, based on the FCG level, at enrollment was associated with tuberculosis treatment failure or death (aOR, 3.3; 95% CI, 1.2-9.3). CONCLUSIONS: Transient hyperglycemia is frequent during tuberculosis, and DM needs confirmation after tuberculosis treatment. Performance of DM screening at tuberculosis diagnosis gives the opportunity to detect patients at risk of adverse outcome.
Authors: Matthew J Magee; Argita D Salindri; Nang Thu Thu Kyaw; Sara C Auld; J Sonya Haw; Guillermo E Umpierrez Journal: Curr Diab Rep Date: 2018-08-09 Impact factor: 4.810
Authors: Huma Aftab; Dirk L Christensen; Atiqa Ambreen; Mohammad Jamil; Peter Garred; Jørgen H Petersen; Susanne D Nielsen; Ib C Bygbjerg Journal: Am J Trop Med Hyg Date: 2017-08-18 Impact factor: 2.345
Authors: V Mave; S Meshram; R Lokhande; D Kadam; S Dharmshale; R Bharadwaj; A Kagal; N Pradhan; S Deshmukh; S Atre; T Sahasrabudhe; M Barthwal; S Meshram; A Kakrani; V Kulkarni; S Raskar; N Suryavanshi; R Shivakoti; S Chon; E Selvin; A Gupte; A Gupta; N Gupte; J E Golub Journal: Int J Tuberc Lung Dis Date: 2017-12-01 Impact factor: 2.373
Authors: Jose Cadena; Selvalakshmi Rathinavelu; Juan C Lopez-Alvarenga; Blanca I Restrepo Journal: Tuberculosis (Edinb) Date: 2019-05-03 Impact factor: 3.131
Authors: Julia A Critchley; Blanca I Restrepo; Katharina Ronacher; Anil Kapur; Andrew A Bremer; Larry S Schlesinger; Randall Basaraba; Hardy Kornfeld; Reinout van Crevel Journal: Chest Date: 2017-04-20 Impact factor: 9.410
Authors: M J Magee; A D Salindri; U P Gujral; S C Auld; J Bao; J S Haw; H-H Lin; H Kornfeld Journal: Int J Tuberc Lung Dis Date: 2018-11-01 Impact factor: 2.373
Authors: A N Gupte; V Mave; S Meshram; R Lokhande; D Kadam; S Dharmshale; R Bharadwaj; A Kagal; N Pradhan; S Deshmukh; S Atre; T Sahasrabudhe; M Barthwal; S Meshram; A Kakrani; V Kulkarni; S Raskar; N Suryavanshi; R Shivakoti; S Chon; E Selvin; N Gupte; A Gupta; J E Golub Journal: Int J Tuberc Lung Dis Date: 2018-07-01 Impact factor: 2.373
Authors: R T Ncube; S A Dube; S M Machekera; C Timire; C Zishiri; K Charambira; T Mapuranga; C Duri; C Sandy; R A Dlodlo; Y Lin Journal: Public Health Action Date: 2019-06-21